EF
GLUE icon

Empowered Funds’s Monte Rosa Therapeutics GLUE Stock Holding History

Empowered Funds’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.97M Buy
329,266
+23,868
+8% +$451K 0.04% 497
2026
Q1 		$5.02M Buy
305,398
+27,321
+10% +$522K 0.03% 636
2025
Q4 		$4.36M Buy
278,077
+190,627
+218% +$2.57M 0.07% 285
2025
Q3 		$648K Buy
+87,450
New +$463K 0.01% 1311

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Empowered Funds's GLUE Position: Q2 2026 in Review

Empowered Funds increased its Monte Rosa Therapeutics (GLUE) stake by 7.8% in Q2 2026, buying an estimated $451K and bringing the position to 329,266 shares worth $7.97M. The position accounts for 0.04% of the portfolio, ranked #497.

Empowered Funds first reported a position in GLUE in Q3 2025 and has held it in 4 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Empowered Funds held 329,266 shares of Monte Rosa Therapeutics worth $7.97M as of Q2 2026.
  • Empowered Funds bought 23,868 Monte Rosa Therapeutics shares in Q2 2026, an estimated $451K.
  • Monte Rosa Therapeutics made up 0.04% of Empowered Funds's portfolio in Q2 2026, its #497 holding.
  • Empowered Funds first reported a position in Monte Rosa Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.